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Abstract
Because the real-world impact of new vaccines cannot be known before they are implemented in 
national programs, post-implementation studies at the population level are critical. Studies based 
on analysis of hospitalization rates of vaccine-preventable outcomes are typically used for this 
purpose. However, estimates of vaccine impact based on hospitalization data are particularly prone 
to confounding, as hospitalization rates are tightly linked to changes in the quality, access and use 
of the healthcare system, which often occur simultaneously with introduction of new vaccines. 
Here we illustrate how changes in healthcare delivery coincident with vaccine introduction can 
influence estimates of vaccine impact, using as an example reductions in infant pneumonia 
hospitalizations after introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) in 
Brazil. To this end, we explore the effect of changes in several metrics of quality and access to 
public healthcare on trends in hospitalization rates before (2008–09) and after (2011–12) PCV10 
introduction in 2010. Changes in infant pneumonia hospitalization rates following vaccine 
introduction were significantly associated with concomitant changes in hospital capacity and the 
fraction of the population using public hospitals. Importantly, reduction of pneumonia 
hospitalization rates after PCV10 were also associated with the expansion of outpatient services in 
several Brazilian states, falling more sharply where primary care coverage and the number of 
health units offering basic and emergency care increased more. We show that adjustments for 
unrelated (non-vaccine) trends commonly employed by impact studies, such as use of single 
control outcomes, are not always sufficient for accurate impact assessment. We discuss several 
ways to identify and overcome such biases, including sensitivity analyses using different 
denominators to calculate hospitalizations rates and methods that track changes in the outpatient 
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setting. Employing these practices can improve the accuracy of vaccine impact estimates, 
particularly in evolving healthcare settings typical of low- and middle-income countries.
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1. Introduction
In recent decades, the use of vaccines against infectious diseases of global importance has 
grown substantially. Efficacy is always assessed in pre-licensure trials before regulators 
approve a new vaccine. However, the real-world impact of vaccines can be greater or smaller 
than efficacy due to indirect factors such as herd immunity and serotype replacement. 
Moreover, pre-licensure trials are performed under idealized conditions and often exclude 
certain high-risk individuals. Therefore, studies that assess the impact of newly introduced 
vaccines on disease rates at the population level are critical.
In real-world populations, however, nothing is static. Estimating vaccine effects with 
accuracy is always complicated by other changes that occur in the population around the 
time the vaccine is introduced. Unrelated trends can be particularly pronounced in rapidly 
developing countries, where the introduction of a new vaccine often occurs concomitant 
with unrelated improvements in public health.
Because population-based surveillance data are rarely available on a large scale, and 
laboratory confirmation of the causative pathogen is often not possible, vaccine impact 
evaluations often rely on proxy measures of disease rates at the community level. Hospital 
admission data have been widely used for that purpose, often by comparing hospitalization 
rates for a disease within the same population before and after vaccine introduction [1–3].
Electronic hospitalization databases are effective tools for public health research, 
surveillance and planning, providing systematic and low-cost information about large 
populations. However, hospitalization data are also prone to specific biases and confounding 
that can affect estimates of vaccine impact, as admission rates are closely linked to changes 
in broad societal trends that affect not only biological susceptibility to disease, but also 
healthcare delivery itself.
Here we investigate how changes in healthcare delivery influence estimates of vaccine 
impact by exploring the association between hospitalization rates and healthcare access and 
quality. As a case study, we focus on changes in infant hospitalization rates for pneumonia 
after introduction of the 10-valent pneumococcal conjugate vaccines (PCV10) in Brazil in 
2010.
Our results indicate that commonly employed adjustments are not always sufficient to 
control for changes in hospitalization rates unrelated to vaccine introduction, particularly in 
evolving healthcare settings. We discuss several ways to identify and address these biases.
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2. Methods
To examine how changes in healthcare use and delivery affect hospitalization rates, we 
calculated several metrics of healthcare utilization, quality, and access before and after 
PCV10 introduction. We then explored how changes in these metrics were associated with 
simultaneous changes in crude hospitalization rates for pneumonia and comparison 
outcomes. We focused the analysis on infants <12 months, the primary group targeted for 
vaccination.
2.1. Data on hospitalizations
In Brazil, access to the public health service is, in principle, universal, and comprehensive 
data are available on people who receive public care (82% of the population in 2012). We 
obtained de-identified, age-stratified monthly data on hospitalizations (Jan2003–Dec2013) 
from the Unified Health System (SIH-SUS, Ministry of Health; [4]), which maintains a 
nationwide database that records all hospitalizations paid by the government. This database 
has been shown to record pneumonia hospitalization incidence in infants as reliably as 
prospectively collected primary hospitalization data [5].
To minimize the number of nosocomial pneumonia cases included in the time series, we 
excluded hospitalizations associated with “treatment packages”—sets of services, supplies 
and procedures—unrelated to community-acquired pneumonia (Table S1). We also excluded 
records in which the “length of stay” field was inconsistent with the discharge and admission 
dates (representing instances where a patient was immediately readmitted following 
discharge). We also excluded records from union, university, and self-financed hospitals, as 
those did not contribute consistently to the database.
2.2. Inpatient healthcare delivery: use of public hospitals and hospital capacity
Although access to public health is universal, some citizens opt for a privately financed tier 
of care perceived to offer better quality and faster access. To determine the size of the infant 
population actually using the public system (SUS) and thus represented in the 
hospitalization database, we subtracted the number of infants enrolled in private insurance 
plans offering hospitalization coverage [6] from the total infant population (Brazilian 
Institute of Geography and Statistics).
We considered hospital bed supply (hospital beds available in SUS; [7]) as a measure of 
hospital capacity.
2.3. Healthcare delivery: outpatient care access and quality
Because many pneumonia hospitalizations are preventable by appropriate care and 
management, improvements in outpatient services at the time of PCV10 introduction might 
reduce pneumonia hospitalizations. We focused on three metrics: (i) the number of health 
units offering basic healthcare services [8]; (ii) the percentage of the population 
appropriately covered by health teams [9], defined by the government as the number of 
teams working in an area multiplied by 3000 (based on the recommendation that each team 
can provide proper care for 3000 people) and divided by the population living in the area, 
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and (iii) the total number of UPAs (Unidades de Pronto Atendimento; [10]), i.e. emergency 
care units placed in many municipalities starting in 2008; UPAs are designed to reduce the 
demand for hospital services, and are equipped to treat cases of higher complexity than basic 
healthcare units.
We also examined potential changes in the quality of outpatient care by analyzing trends in 
rates of “potentially avoidable hospitalizations” (PAHs), a group of disease outcomes often 
used as an indicator of primary care quality; we used the list of PAHs adopted by the 
Brazilian government (Table S2). In theory, improvements in prevention and early disease 
management at the outpatient setting should lower PAH rates.
2.4. PCV10 uptake
Brazil introduced PCV10 in its National Immunization Program (PNI) in March 2010. To 
estimate PCV10 coverage, we calculated the percentage of eligible infants (6–23 months) 
who had at least the 3 recommended routine doses (at 2, 4 and 6 months) using the age-
cohort method described in [11]. Data on doses administered by state, month and age was 
provided by PNI [12]; live birth statistics (SINASC, [13]) were used to estimate rates. 
Nationally, PCV10 coverage reached 33%, 76% and 89% by December 2010, 2011 and 
2012, respectively.
2.5. Data analysis
We first examined the consistency of ICD10 pneumonia coding from 2003 to 2012. We 
found that the pattern of codes assigned for many disorders changed dramatically in January 
2008, coincident with substantial changes in the system used to reimburse hospitals, which 
relaxed the specificity of ICD10 reporting requirements. For example, the frequency of 
pathogen-specific codes such as J13 (pneumococcal pneumonia) and J14 (H. influenzae 
pneumonia) fell sharply, while the number of J18 codes (pneumonia, organism unspecified) 
rose (Fig. S1). We therefore limited our pre-post analysis to the period starting in January 
2008.
We next tested the association between changes in hospitalization rates before and after 
PCV10 introduction and concomitant changes in the healthcare metrics previously 
described. Changes in hospitalization rates were estimated as in [14], by calculating the ratio 
(incidence rate ratio, or IRR) between the average annual incidence rate two years post-PCV 
(2011–12) and two years pre-PCV10 (2008–09), with their corresponding 95% confidence 
intervals [15]. The association between IRR and relative changes in healthcare metrics were 
tested with Pearson and Spearman correlations.
Because our aim was to illustrate the effect of broader changes in healthcare delivery on 
simultaneous changes in crude rates of hospitalization rather than to estimate vaccine impact 
itself, we did not attempt to determine the adjusted impact of PCV10 using models or 
methods other than the calculation of IRRs. IRRs reported here should therefore not be taken 
as estimates of PCV10 impact; they are only used to illustrate the effect of the potentially 
confounding trends discussed on hospitalization rates for pneumonia.
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Pre-post PCV10 IRR estimates, calculated as described above, were computed for all-cause 
pneumonia (ICD10 J12–18), respiratory disease (J00–99), infectious diseases other than 
diarrhea (A10-B99), which was excluded to avoid confounding by rotavirus vaccine 
introduction in Brazil, and all hospitalizations (all causes). We conducted the analyses both 
at a national and state level, to take advantage of variability in the timing at which the states 
introduced changes in the health system.
We also analyzed whether putative associations between improvements in healthcare and 
reductions in hospitalizations for pneumonia were a by-product of differences in PCV10 
coverage among states, given that in states where the health system improved more, PCV10 
coverage may have been higher, driving pneumonia hospitalizations down. To this end, we 
tested the association between PCV10 coverage (at December 2010, 2011 and 2012) and 
IRRs for all-cause pneumonia (Pearson correlation). We also tested whether PCV10 
coverage was associated with changes in healthcare delivery.
Data extraction and processing were performed with SAS 9.3. IRR estimates were calculated 
in Excel, and all correlations with Minitab v.17.3.1.
3. Results
3.1. Effect of changes in the population using hospitals in the public system
Estimates of vaccine impact depend on how well the denominator used to calculate 
hospitalization rates represents the population using hospitals. From 2008 to 2012, the infant 
population dropped by 7% (from 3.1 to 2.8 million infants). Moreover, the percentage of 
Brazilian infants who participated in the SUS system, and who thus contributed to the data, 
fell from 85% to 83% (from 2.6 to 2.3 million infants). When using the total Brazil 
population of infants as the denominator, the IRR for pneumonia was 0.89 (95%CI 0.88–
0.90)—an 11.3% drop nationwide, but only 0.92 (95% CI 0.91–0.93)—a 7.8% drop—when 
the SUS population was used as the denominator (Table 1). That represents a 30.8% 
difference between estimates. In all regions, denominating pneumonia hospitalizations by 
the SUS population rather than the total population reduced the magnitude of the drop in 
hospitalization rates (Table 1); the difference was greatest in the Southeast, with the 
estimated drop almost halving when using SUS population (from 11.5 to 6.5%).
3.2. Effect of changes in inpatient healthcare delivery systems
Public health care (SUS) is provided in Brazil through both nonprofit (government-owned 
and philanthropic) and for-profit hospitals (under contract to provide beds to the public 
system). Nationally, the supply of public hospital beds provided through both for-profit and 
nonprofit hospitals dropped by approximately 5% from 2008 to 2012 (from 2.2 to 2.1/1000 
population). For each Brazilian state, we plotted the change in the number of beds available 
per 1000 infants against IRR. We found that reductions in hospitalization rates for 
pneumonia were sharper in states where bed loss was more pronounced (Fig. 1). Strong 
associations between bed loss and IRR were also observed for the other outcomes, 
particularly all-cause hospitalizations (Fig. 1).
Schuck-Paim et al. Page 5
Vaccine. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Changes in public bed supply, however, were different among for-profit and non-profit 
hospitals. In for-profit hospitals, beds made available to SUS fell 13% from 2008 to 12 
(from 0.89 to 0.77 beds/1000), but increased 5% among non profit hospitals, from 1.29 to 
1.36 beds/1000. We hypothesized that if the number of available beds affects admissions, 
declines in hospitalization rates would be greater in for-profit hospitals. We found this to be 
the case (Table 2), with a greater decline in pneumonia hospitalizations in for-profit (IRR = 
0.70; 95%CI 0.68–0.71) than nonprofit facilities (IRR = 0.98; 95%CI 0.97–0.99). We found 
a similar result for all respiratory outcomes (J00–99; Table 2), suggesting that IRR 
differences between for-profit and non-profit hospitals were not due to differences in risk 
factors for pneumonia or PCV coverage between them. There was no significant association 
between bed loss and PCV10 coverage (p > 0.05).
Because all-cause hospitalizations track the total capacity of the hospitalization system, we 
next calculated IRRs for pneumonia and respiratory disease using the total number of 
hospitalizations as the denominator. Overall, there were large differences in estimated IRRs 
between the analysis using SUS population and total hospitalizations as the denominator 
(Table 2). In the latter case, IRR differences between for-profit and non-profit were 
substantially reduced or were not significant.
3.3. Effect of changes in outpatient healthcare delivery system
From Jan-2008 to Dec-2012, the proportion of the population covered by appropriate 
primary care teams (see Methods) increased nationwide from 64% to 67%. Similarly, the 
number of outpatient units providing basic care services increased from 96,000 to 115,000 
units. At the same time, the proportion of hospitalizations classified as potentially avoidable 
(PAHs, an indicator of primary care quality; see Methods) relative to total hospitalizations 
fell from 30% to 25%.
In line with the expectation that most pneumonia hospitalizations are potentially avoidable 
given appropriate primary care, rate reductions for pneumonia were larger in those states 
where primary care coverage increased more (Fig. 2), and in states that experienced a larger 
growth in the number of units providing basic healthcare services (Fig. 2). Significant 
correlations (Pearson; r = −0.34 to −0.49; p < 0.05) in the same direction were also found for 
respiratory disease (J00–99), and all-cause hospitalizations, but not for infectious diseases 
(A10-B99). These findings were not driven by differences in PCV10 coverage among states, 
as PCV10 coverage was not significantly correlated with any of the changes described.
We examined whether the increasing availability of UPAs (new emergency outpatient units; 
see Methods) was associated with a reduction in pneumonia hospitalization rates following 
PCV10 introduction. We found that in states that created more UPAs up to 2012, rate 
reductions in pneumonia hospitalizations were also greater (Fig. 2).
4. Discussion
Observational studies of trends in hospitalizations have been widely and productively used 
to estimate disease burden and the impact of vaccines [16–20]. However, attributing changes 
in hospitalization rates before and after the start of an intervention specifically to that 
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intervention can be challenging, and may lead to an over- or under-estimation of benefits in 
countries where the healthcare system is itself evolving. Because such changes often occur 
rapidly in low- and middle-income countries, one must be particularly cautious in such 
settings, especially if the expected impact of a vaccine is relatively modest. In Table 3 we 
summarize prior studies of PCV impact on all-cause pneumonia hospitalizations in Latin 
America, and their use of different practices that might help to identify or adjust for such 
biases.
In Brazil, we found a positive association between the supply of hospital beds and rates of 
hospitalization for pneumonia; others have published similar findings [21,22]. This suggests 
that hospitals were operating at full capacity, an observation corroborated by a recent report 
showing that most public hospitals in Brazil cannot meet demand for services [23]. Indeed, 
the 2.2 beds per 1000 persons in 2008 was less than half the European average of 5.5 beds/
1000 that same year [24].
Interpreting trends in disease rates inferred from hospitalization data is difficult when 
hospitals are running at or over capacity. In such circumstances, higher community-acquired 
disease rates may not translate into proportional increases in hospitalizations because 
hospitals would not be able to meet the increased demand. Conversely, lowered disease rates 
could be partially or even fully masked, as hospitalization databases have no records of 
potential patients turned away due to lack of available beds.
Using all-cause hospitalizations to denominate hospitalization rates can help control for 
changes in hospital capacity. Additionally, all-cause hospitalizations can track and adjust for 
changes in the population using target hospitals – such as those caused by the migration to 
private insurance. However, if hospitals are operating at full capacity, and the target disease 
and/or age group studied has a different admission priority compared to other groups (e.g. 
pneumonia is high-priority in Brazil), denomination by all-cause hospitalizations can also 
result in biased estimates. For example, if the incidence of community-acquired pneumonia 
cases is unchanged (i.e. pneumonia cases decline proportionally with decreases in 
population size), hospital beds freed from pneumonia cases will be used for other conditions. 
Accordingly, the proportion of pneumonia over all-cause hospitalizations will reduce due to 
such non-vaccine related changes. Therefore, considering changes in both population size 
and all-cause hospitalizations when hospitals operate over capacity is critical.
Importantly, denomination by either all-cause hospitalizations or population does not prevent 
introduction of bias caused by changes in outpatient services [25]. In Brazil, expansion of 
outpatient care services was associated with reduced hospitalizations for pneumonia and 
other outcomes, indicating that changes in this setting can be an important source of 
confounding. For example, in 2006 Brazil introduced a nationwide program called ‘Pact for 
Health’. One of its goals was to reduce diarrhea and pneumonia deaths in young children. 
The program created local committees to monitor child mortality and trained medical staff in 
proper treatment of these diseases. These measures likely added to the effect of 
immunization programs, such as the introduction of the rotavirus vaccine in the same year.
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One way to identify biases resulting from changes in outpatient care is the analysis of 
outcomes that are affected by factors that also affect the vaccine target, but are themselves 
unaffected by the vaccine [26]. Since changes in outpatient care can introduce bias, such 
comparison outcomes should be similarly sensitive to such changes. Because PAHs are by 
design sensitive to primary care [27–29], it may be possible to use trends in PAH rates, or 
appropriate subsets, as a proxy for changes in primary care quality. Alternatively, “synthetic 
controls” has been shown to provide a data-driven solution to control for unrelated trends in 
disease rates [30]. In this approach, time series of outcomes assumed to be unaffected by the 
vaccine are weighted and combined into a single composite time series depending on their 
fit to the time series of interest (e.g., pneumonia) before vaccine introduction. The composite 
“synthetic control” is then calculated by applying the weights from the pre-vaccine period to 
the outcome incidences in the post-vaccine period, producing a counterfactual estimate of 
disease rates had no vaccine been in use. This method does not require a priori qualitative 
decisions on what constitutes an appropriate control, which can itself introduce bias. 
Another option is to analyze inpatient and outpatient trends simultaneously (e.g. [31]). If the 
vaccine works as expected, and disease etiology is not different between these settings, the 
burden of both hospitalizations and outpatient visits for the vaccine target should fall.
Of the studies summarized in Table 3, three [32–34] did not seek to adjust for secular trends, 
potential biases and confounding. Seven addressed potential biases arising from changes in 
inpatient care by using all-cause hospitalizations as a denominator [35–37], analyzing 
control outcomes possibly with similar admission priority [20,31,35] or directly analyzing 
hospital capacity [38]. Similarly, five used controls potentially sensitive to primary care 
changes [20,31,36] or examined outpatient data [31,39,40]. The analysis of secular trends 
[20,38,39,41] and single control outcomes [20,31,36,41] can help control biases, but may 
not have been sufficient to control them completely. For example, the potential reduction in 
pneumonia hospitalizations resulting from the creation of over 500 UPAs in 2010–2012 (just 
after PCV10 introduction in Brazil) may not be captured by these adjustments. Other 
unrelated events may also affect hospitalization rates in the pre- (e.g., 2009 influenza 
pandemic) or post-PCV periods if not properly adjusted.
In conclusion, caution is needed when attributing changing trends in hospitalization rates to 
vaccines. We suggest that in addition to considering secular trends, impact studies based on 
hospitalization data present sensitivity analyses showing the effect of using various 
denominators, adjust for the potential effect of changes in both the inpatient and outpatient 
settings and use comparison outcomes that also share similar hospital admission priority and 
sensitivity to primary care changes with the target disease. These practices would strengthen 
efforts to understand how vaccines translate into reductions of disease burden, especially 
where cost-effective interventions are most needed.
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Fig. 1. 
Relative change in hospital beds in the public health system. Bed availability per 100,000 
population in 2011–12 vs. 2008–09 (IRRbeds) is plotted against change in hospitalization 
rates in 2011–12 vs. 2008–09 (IRRhosp). In states where bed availability decreased more 
(lower IRRbeds), the estimated drop in hospitalization rates was also larger (lower IRRhosp). 
Pearson correlation: J12–18 (r = 0.46, p < 0.05); J00–99 (r = 0.55, p < 0.01); A10-B99 (r = 
0.47, p < 0.05); all-causes (r = 0.66, p < 0.001).
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Fig. 2. 
Incidence rate ratio (IRR) for pneumonia (J12–18) in infants (post/pre PCV10 introduction) 
and three measures of change in outpatient healthcare (post- vs. pre-PCV10). Larger drops 
in pneumonia hospitalization rates (lower IRR) were achieved in those states where 
improvements in access to primary care were larger. Pearson correlation between IRR for 
pneumonia and: A (r = −0.57, p < 0.01); B (r = −0.43, p < 0.05); C (r = −0.52, p < 0.01).
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Table 2
The effect of using SUS population and all-cause hospitalizations as the denominator when calculating 
incidence rate ratios (IRR) (2011–12 vs. 2008–09 pneumonia hospitalization rates) in nonprofit and for-profit 
hospitals providing care to SUS patients.
Disease outcome Effect of changes in bed availability
IRR (95% CI) in nonprofit
hospitals in SUS system
IRR (95% CI) in for-profit
Hospitals in SUS system
Effect of 
denominator used to 
calculate IRR
SUS population as 
denominator
Pneumonia (J12–18) 0.98 (0.97–0.99) 0.70 (0.68–0.71)
All Respiratory (J00–99) 1.04 (1.03–1.05) 0.71 (0.70–0.72)
All-cause hospitalizations 
as denominator
Pneumonia (J12–18) 0.87 (0.86–0.88) 0.92 (0.90–0.94)
All Respiratory (J00–99) 0.92 (0.91–0.93) 0.92 (0.90–0.94)
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